ReviewCurrent hypertension reports2012
Target organ damage in African American hypertension: role of APOL1.
Review in Current hypertension reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 57 citations in OpenAlex.
- Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Impact of abdominal obesity indices on all-cause and cardiovascular mortality in individuals with pre-diabetes and diabetes: insights from a prospective cohort study.BMC public health · 2025Article
- Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.Kidney international · 2024Article
- Management of Type 2 Diabetes Mellitus and Kidney Failure in People with HIV-Infection in Africa: Current Status and a Call to Action.HIV/AIDS (Auckland, N.Z.) · 2023Review
- Outcomes of Hypertensive Kidney Donors Using Current and Past Hypertension Definitions.Kidney international reports · 2021Article
- Kidney disease and APOL1.Human molecular genetics · 2021Review
- Pharmacotherapeutic options for kidney disease in HIV positive patients.Expert opinion on pharmacotherapy · 2021Review
- Replication of European hypertension associations in a case-control study of 9,534 African Americans.PloS one · 2021Article
- Blood Pressure and Living Kidney Donors: A Clinical Perspective.Transplantation direct · 2019Article
- Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.American journal of nephrology · 2018Review
- Psychosocial Factors and Hypertension: A Review of the Literature.Cardiology clinics · 2017Review
- Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans.Journal of the American College of Cardiology · 2017Article
- Hypertension-attributed nephropathy: what's in a name?Nature reviews. Nephrology · 2016Review
- Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.Pediatric nephrology (Berlin, Germany) · 2015Article
- Assessment and management of hypertension in transplant patients.Journal of the American Society of Nephrology : JASN · 2015Review
- Morphology in the Digital Age: Integrating High-Resolution Description of Structural Alterations With Phenotypes and Genotypes.Seminars in nephrology · 2015Review
- Understanding the Importance of Race/Ethnicity in the Care of the Hypertensive Patient.Current hypertension reports · 2015Review
- Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2014Review
- Neighborhood socioeconomic status, race, and mortality in young adult dialysis patients.Journal of the American Society of Nephrology : JASN · 2014Article
- Familial clustering of ESRD in the Norwegian population.Clinical journal of the American Society of Nephrology : CJASN · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Apolipoprotein L1 (APOL1) gene association studies and results of the African American Study of Kidney Disease and Hypertension are disproving the longstanding concept that mild to moderate essential hypertension contributes substantially to end-stage renal disease susceptibility in African Americans. APOL1 coding variants underlie a spectrum of kidney diseases, including that attributed to hypertension (labeled arteriolar or hypertensive nephrosclerosis), focal segmental glomerulosclerosis, and HIV-associated nephropathy. APOL1 nephropathy risk variants persist because of protection afforded from the parasite that causes African sleeping sickness. This breakthrough will lead to novel treatments for hypertensive African Americans with low-level proteinuria, for whom effective therapies are lacking. Furthermore, APOL1 nephropathy risk variants contribute to racially variable allograft survival rates after kidney transplantation and assist in detecting nondiabetic forms of nephropathy in African Americans with diabetes. Discovery of APOL1-associated nephropathy was a major success of the genetics revolution, demonstrating that secondary hypertension is typically present in nondiabetic African Americans with nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.